藥易購(300937.SZ):控股子公司擬建設MAH成果轉化平台
格隆匯10月23日丨藥易購(300937.SZ)公佈,公司於2022年10月21日召開第三屆董事會第三次會議,審議通過了《關於控股子公司對外簽署投資協議暨公司對全資子公司增資的議案》。
隨着藥品上市許可持有人(簡稱“MAH”)制度的正式頒佈實施,中國醫藥產業呈現出更多更靈活的投資和發展機會,為順應國家醫藥產業發展大趨勢,公司擬通過增資公司全資子公司四川合縱澤輝醫藥科技有限公司(簡稱“合縱澤輝”)的方式,後續依法依規申請成為藥品生產許可證B證公司,並依託該公司建設MAH持證轉化平台。
為推進項目的順利落地和後續發展,公司控股子公司海南美迪康生物科技有限公司擬與彭州市天府中藥城管理委員會簽署投資協議,總投資約3000萬元人民幣,項目實施內容為擬建設MAH成果轉化平台。
公司已於2022年7月6日設立全資子公司合縱澤輝,合縱澤輝將作為未來MAH持證轉化平台的主體公司,公司擬使用自有資金對合縱澤輝進行增資,增資後註冊資本將由100萬元人民幣增加至2000萬元人民幣。增資後,公司對合縱澤輝持股比例不變,合縱澤輝仍為公司全資子公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.